These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. Apud JA; Weinberger DR CNS Drugs; 2007; 21(7):535-57. PubMed ID: 17579498 [TBL] [Abstract][Full Text] [Related]
8. Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia? Laviolette SR Schizophr Bull; 2007 Jul; 33(4):971-81. PubMed ID: 17519393 [TBL] [Abstract][Full Text] [Related]
9. Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective. Tanaka S Neuroscience; 2006 Apr; 139(1):153-71. PubMed ID: 16324800 [TBL] [Abstract][Full Text] [Related]
10. Schizophrenia: from phenomenology to neurobiology. Wong AH; Van Tol HH Neurosci Biobehav Rev; 2003 May; 27(3):269-306. PubMed ID: 12788337 [TBL] [Abstract][Full Text] [Related]
11. The neurobiology of schizophrenia. Littrell RA; Schneiderhan M Pharmacotherapy; 1996; 16(6 Pt 2):143S-147S; discussion 166S-168S. PubMed ID: 8947997 [TBL] [Abstract][Full Text] [Related]
13. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment. Snyder GL; Vanover KE Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266 [TBL] [Abstract][Full Text] [Related]
14. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Castner SA; Goldman-Rakic PS; Williams GV Psychopharmacology (Berl); 2004 Jun; 174(1):111-25. PubMed ID: 15205882 [TBL] [Abstract][Full Text] [Related]
15. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia]. Kolomeets NS Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378 [TBL] [Abstract][Full Text] [Related]
16. Primate phencyclidine model of schizophrenia: sex-specific effects on cognition, brain derived neurotrophic factor, spine synapses, and dopamine turnover in prefrontal cortex. Elsworth JD; Groman SM; Jentsch JD; Leranth C; Redmond DE; Kim JD; Diano S; Roth RH Int J Neuropsychopharmacol; 2014 Oct; 18(6):. PubMed ID: 25522392 [TBL] [Abstract][Full Text] [Related]
17. [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia]. Heinz A; Braus DF; Romero B; Gallinat J; Puls I; Juckel G; Weinberger DR Nervenarzt; 2004 Sep; 75(9):845-56. PubMed ID: 15372159 [TBL] [Abstract][Full Text] [Related]
18. Schizophrenia: from dopaminergic to glutamatergic interventions. Laruelle M Curr Opin Pharmacol; 2014 Feb; 14():97-102. PubMed ID: 24524997 [TBL] [Abstract][Full Text] [Related]
19. Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Meyer U; Feldon J Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759 [TBL] [Abstract][Full Text] [Related]
20. PDE Inhibitors for the Treatment of Schizophrenia. Snyder GL; Vanover KE Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]